Carrington Laboratories Promotes Dr. Sheri H. Smith To Top Position In Advanced Wound Care Division

New VP, Medical Services, Cited For Extensive Background In Clinical Research, Marketing, Product Development, Professional Education

IRVING, Texas, Oct. 23 /PRNewswire-FirstCall/ -- Carrington Laboratories, Inc. (Nasdaq: CARN) today announced that Sheri H. Smith, Ph.D., CETN, an award-winning researcher, educator and wound-care consultant, has been promoted to vice president, medical services. Dr. Smith, 45, had been Carrington's assistant medical director since 1996. Prior to joining Carrington, Dr. Smith provided wound care consulting services to medical professionals and facilities.

"Dr. Smith's first-hand knowledge of the clinical efficacy of our advanced wound care products, combined with a solid foundation in product development, costing and marketing, uniquely qualify her for the top position in our wound care division," said Carlton E. Turner, president and chief executive officer. "Over the past six years she has been a key figure in further developing the market for our products with activities including educating medical professionals, conducting clinical and case studies and writing wound care protocols."

Dr. Smith, who earned her doctorate at the University of Alabama, is board certified in wound, ostomy and continence nursing and is a certified wound specialist. She is an active member of the American Nurses Association and the Wound Ostomy and Continence Nurses Society (WOCN) and has authored a number of papers published in the "WOCN Journal" and other professional publications. She won the Southeast Region WOCN Research Award in 1996. Prior to becoming a wound-care consultant, Dr. Smith held various nursing and teaching positions.

About Carrington

Carrington Laboratories, Inc., is an ISO 9001-certified, research-based biopharmaceutical company currently utilizing naturally occurring complex carbohydrates to manufacture and market products for mucositis, radiation dermatitis, wound and oral care; manufacture and market the nutraceutical raw materials Manapol(R) and Hydrapol(TM); and market consumer products under the AloeCeuticals(R) brand. Carrington's technology is protected by more than 120 patents in 26 countries. Select products are honored with the internationally coveted CE mark, recognized by more than 20 countries around the world.

Certain statements in this release concerning Carrington may be forward-looking. Actual events will be dependent upon a number of factors and risks including, but not limited to: subsequent changes in plans by the company's management; delays or problems in production; changes in the regulatory process; changes in market trends; and a number of other factors and risks described from time to time in the Company's filings with the Securities & Exchange Commission, including the Form 10Q filed August 14, 2002.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.